Impact of COVID-19 on candidemia: Risk factors and outcomes in a southeastern US cohort
Medical Mycology · 2025
DOI: 10.1093/mmy/myaf103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Mycology, 2025. Verfasst von Melat Endashaw und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Emory Healthcare, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Candidemia, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Center for Advancing Translational Sciences of the National Institutes of Health.
Abstract (Originalsprache)
Candidemia cases increased during the COVID-19 pandemic, likely due to increased critical care interventions. However, the pandemic’s impact on candidemia risk factors and outcomes remains understudied. The objective of this study was to evaluate changes in candidemia risk factors and in-hospital mortality before and during the COVID-19 pandemic, stratified by COVID-19 status. We retrospectively analyzed adult candidemia cases (defined by Candida species isolated from blood cultures) at a single center in Albany, Georgia, USA (January 2017–May 2023). Patients were grouped as (1) pre-pandemic, (2) pandemic with COVID-19, and (3) pandemic without COVID-19. Clinical characteristics, risk factors, and in-hospital mortality were compared across groups. Among 89 patients (44% pre-pandemic, 56% pandemic [50% with COVID-19]), comorbidities were highest pre-pandemic (P = .008), though 12% of patients with COVID-19 had none (vs. 0% pre-pandemic, 4% non-COVID-19; P = .01). Candidemia was more often diagnosed in the ICU among the COVID-19 group (92%) compared to pre-pandemic (49%) and non-COVID-19 pandemic groups (44%) (P < .001). Mechanical ventilation (88%) and vascular catheter use (96%) were also higher in the COVID-19 group (P < .001 for both). Glucocorticoid use was more frequent in the COVID-19 group (76%) versus pre-pandemic (18%) and non-COVID-19 pandemic groups (24%) (P = .008). In-hospital mortality was highest in the COVID-19 group (76%) compared to the pre-pandemic (44%) and non-COVID-19 pandemic groups (32%) (P < .001). Patients with COVID-19 had a higher prevalence of risk factors for candidemia and significantly worse clinical outcomes, including increased in-hospital mortality, compared to other groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Emory Healthcare, Atlanta, GA, USA.
- Department of Pharmacy, Wellstar MCG Health, Augusta, GA, USA.
- Department of Pharmacy, University of Alabama at Birmingham Hospital, Birmingham, Alabama, USA.
- Department of Pharmacy, Grady Memorial Hospital, Atlanta, Georgia, USA.
- Department of Pharmacy, Piedmont Columbus Regional Midtown, Columbus, Georgia, USA.
- Department of Statistics, University of Georgia Franklin College of Arts and Sciences, Athens, Georgia, USA.
ORCID-Profile: Xianyan Chen, Andrés F Henao-Martínez, Daniel B Chastain
Förderung
- National Center for Advancing Translational Sciences of the National Institutes of Health
Zitieren
APA
Endashaw, M., Dykes, A., Clark, R., Warrayat, L., Hodges, M. J., Deng, S., Chen, X., Henao-Martínez, A. F., & Chastain, D. B. (2025). Impact of COVID-19 on candidemia: Risk factors and outcomes in a southeastern US cohort. Medical Mycology. https://doi.org/10.1093/mmy/myaf103
Vancouver
Endashaw M, Dykes A, Clark R, Warrayat L, Hodges MJ, Deng S, et al. Impact of COVID-19 on candidemia: Risk factors and outcomes in a southeastern US cohort. Medical Mycology. 2025. doi:10.1093/mmy/myaf103
BibTeX
@article{Endashaw2025,
author = {Endashaw, Melat and Dykes, Austin and Clark, Rachael and Warrayat, Laila and Hodges, McKenzie J and Deng, Shiyuan and Chen, Xianyan and Henao-Martínez, Andrés F and Chastain, Daniel B},
title = {Impact of COVID-19 on candidemia: Risk factors and outcomes in a southeastern US cohort},
journal = {Medical Mycology},
year = {2025},
doi = {10.1093/mmy/myaf103}
}
EUVIMED